TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7648821
Drug: Urinary albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary albumin excretion rate (UAE)
Study: 328880
Drug: Ketoprofen (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (150-300 mg daily)
Study: 328880
Drug: Ibuprofen (1200-2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1200-2400 mg daily)
Study: 31712348
Drug: Intensive skin
Normalized name: Remedy Intensive Skin Therapy Hydraguard D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive skin surveillance programme consisting of 3D total-body photography, sequential digital dermoscopy, and melanoma-risk stratification.
Study: 28206732
Drug: MPFF 1000-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPFF 1000-mg oral suspension once daily
Study: 28206732
Drug: MPFF 500-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPFF 500-mg tablets twice daily
Study: 19336514
Drug: Inhaled GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled GH
Study: 19336514
Drug: Subcutaneous GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous GH (sc GH)
Study: 19336514
Drug: Inhaled GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled GH and sc GH
Study: 16672024
Drug: Resorbable screws
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Resorbable screws made of poly (D.L‐lactide) acid (PDLLA)
Study: 15475033
Drug: Aged Garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged Garlic Extract (AGE) 4 ml
Study: 1839436
Drug: Amlodipine (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (once daily)
Study: 1839436
Drug: Captopril (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (twice daily)
Study: 6223583
Drug: SPG (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPG (20 mg twice a week or 40 mg once a week) in combination with tegafur
Study: 6223583
Drug: SPG (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPG (20 mg twice a week or 40 mg once a week)
Study: 27918841
Drug: summerMAX treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: summerMAX treatment (5-week program targeting social skills, nonliteral language skills, face-emotion recognition, interest expansion)
Study: 27918841
Drug: summerMAX treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: summerMAX treatment
Study: 17444308
Drug: Morphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine plus 0.25 mg/kg ketamine
Study: 9696475
Drug: Capsaicin treatment
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin treatment
Study: 2782361
Drug: Hydration (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration (5% dextrose in lactated Ringer's solution, intravenous bolus and continuous infusion)
Study: 31173127
Drug: High NUF
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High NUF rate (>1.75 mL/kg/h)
Study: 31173127
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in NUF rate (every 0.5 mL/kg/h)
Study: 28651403
Drug: Daily group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily group
Study: 28651403
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between daily and intermittent groups
Study: 15317700
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (15 mg/kg) half an hour before surgery
Study: 15317700
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (0.5 mg/kg) for 2 weeks, tapered postoperatively
Study: 15317700
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Intravenous methylprednisolone and Oral prednisolone)
Study: 9071936
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g coarse bran
Study: 9071936
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g inert plastic particles
Study: 9071936
Drug: 7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g ispaghula
Study: 2881183
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Beta-blockade + Nifedipine)
Study: 30958141
Drug: Stress reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress reduction intervention (5-weekly sessions)
Study: 27181070
Drug: biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: biphasic insulin aspart 30
Study: 23848405
Drug: 1 μg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg.kg(‐1) intranasal dexmedetomidine with 3 mg.kg(‐1) oral ketamine (Group 1)
Study: 23848405
Drug: 1 μg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg.kg(‐1) intranasal dexmedetomidine with 5 mg.kg(‐1) oral ketamine (Group 2)
Study: 23848405
Drug: 2 μg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg.kg(‐1) intranasal dexmedetomidine with 3 mg.kg(‐1) oral ketamine (Group 3)
Study: 23848405
Drug: 2 μg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg.kg(‐1) intranasal dexmedetomidine with 5 mg.kg(‐1) oral ketamine (Group 4)
Study: 8914773
Drug: HIV‐1MN recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV‐1MN recombinant gp120 (rgp120) vaccine
Study: 8914773
Drug: HIV‐1MN recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV‐1MN recombinant gp120 (rgp120) vaccine with HIV‐1IIIB rgp120 vaccine
Study: 6881177
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment (intravenous bolus of methylprednisolone followed by an eight-day tapering course of oral methylprednisolone starting at 32 mg twice a day)
Study: 29232351
Drug: Intraurethral 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraurethral 2% lidocaine jelly administered via Uro‐Jet, 5 minutes before TUBC.
Study: 24055512
Drug: Vacuum-assisted wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum-assisted wound closure (VAC) therapy
Study: 24055512
Drug: Alginate (Sorbalgon)
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate (Sorbalgon) therapy
Study: 24055512
Drug: Alginate therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate therapy
Study: 22429343
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg vitamin C plus 10 mg zinc
Study: 19076086
Drug: Multicenter randomized
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicenter randomized trials and novel classes of drugs and interventional catheter technologies
Study: 15919685
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (non-anthracycline-based)
Study: 10889132
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of angiotensin-converting enzyme inhibitors
Study: 8821417
Drug: N-acetylcysteine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (100 mg/kg body weight)
Study: 8821417
Drug: Streptokinase without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase without further treatment
Study: 1431255
Drug: HA-1A (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-1A (100 mg intravenous single dose)
Study: 31050833
Drug: Aspirin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin at doses below 75 mg daily
Study: 31050833
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants at doses 1/4 of those recommended for atrial fibrillation
Study: 31050833
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of antithrombotics than currently recommended
Study: 24819710
Drug: Stepwise protocol
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepwise protocol of treating pain (SPTP) with acetaminophen, morphine, buprenorphine transdermal patch, and pregabalin for 8 weeks
Study: 20959429
Drug: BIBN4096BS (olcegepant)
Normalized name: Olcegepant
DrugBank: Olcegepant (DB04869)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBN4096BS (olcegepant) 10 mg
Study: 10688397
Drug: Tobramycin solution
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin solution for inhalation (TOBI) for 24 weeks
Study: 9778488
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose inhaled fluticasone propionate (250 mcg bd)
Study: 8105814
Drug: Early neuroleptic
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early neuroleptic intervention treatment
Study: 3536947
Drug: Preincisional presternal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preincisional presternal antibiotic infiltration (2%)
Study: 27133971
Drug: Universal pre-procedural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal pre-procedural indometacin (100 mg rectal indometacin within 30 min before ERCP)
Study: 24184292
Drug: No light
Normalized name: OCTINOXATE 67 mg in 1 mL / TITANIUM DIOXIDE 18 mg in 1 mL TOPICAL LOTION [Valentino Very Valentino Light Lasting Perfecting Foundation Broad Spectrum SPF 26 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No light therapy (after Luminette® use)
Study: 18378381
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin therapy (Control group)
Study: 16685353
Drug: Niuhuangjiedu tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niuhuangjiedu tablets (control)
Study: 14533985
Drug: rhu‐GM‐CSF (125mg/M(2))
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhu‐GM‐CSF (125mg/M(2)) injected subcutaneously twice weekly for four weeks
Study: 10943575
Drug: Ethinylestradiol/drospirenone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol/drospirenone (30 microg ethinylestradiol and 3 mg drospirenone)
Study: 1544778
Drug: Acetazolamide 500
Normalized name: acetazolamide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 500 mg vs Placebo
Study: 3534203
Drug: Amoxicillin plus
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin plus clavulanate (40 mg/kg amoxicillin plus 10 mg/kg clavulanate, total daily doses in three divided doses)
Study: 3534203
Drug: Cefaclor (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (40 mg/kg)
Study: 27454547
Drug: Lurasidone 20
Normalized name: lurasidone 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 20 mg/d
Study: 7929868
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of controlled-release metoprolol
Study: 7929868
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of atenolol
Study: 22810476
Drug: Perianal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perianal administration of 0.4% nitroglycerin ointment (375 mg containing 1.5 mg glyceryl trinitrate), applied every 12 hours for 8 weeks
Study: 22810476
Drug: Endoanal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoanal administration of 0.4% nitroglycerin ointment (375 mg containing 1.5 mg glyceryl trinitrate), applied every 12 hours for 8 weeks
Study: 22810476
Drug: Perianal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perianal administration
Study: 22810476
Drug: Endoanal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoanal administration
Study: 19955824
Drug: Cinacalcet for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet for 6 months in group L (gland >=500 mm(3))
Study: 19955824
Drug: Cinacalcet for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet for 6 months in both groups S and L
Study: 15545508
Drug: COX‐2‐specific inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX‐2‐specific inhibitors
Study: 8767599
Drug: Physical training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical training + low-dose heparin calcium (12,500 IU/day for 6 months)
Study: 1751265
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose lignocaine (mean plasma concentration 0.92 micrograms ml‐1)
Study: 1751265
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose lignocaine (mean plasma concentration 1.78 micrograms ml‐1)
Study: 1751265
Drug: Lignocaine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine (both doses)
Study: 26362760
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with peanut for 12 months
Study: 25321447
Drug: Endobronchial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial therapy (treatment group)
Study: 20001969
Drug: GIK (glucose-insulin-potassium)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK (glucose-insulin-potassium) infusion
Study: 18312520
Drug: Infusion injection
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion injection of rocuronium (I0.6, I0.9)
Study: 18312520
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of rocuronium (B0.6, B0.9)
Study: 15670545
Drug: Rosuvastatin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (various doses)
Study: 15670545
Drug: Atorvastatin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (various doses)
Study: 15670545
Drug: Simvastatin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (various doses)
Study: 15670545
Drug: Pravastatin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (various doses)
Study: 15670545
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with rosuvastatin, atorvastatin, simvastatin, and pravastatin
Study: 14746860
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) at a dose of 80 mg/m(2) every 14 days for four courses, followed by delayed surgery and two more similar CDDP courses for SR-HB patients.
Study: 14746860
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) alternating every 14 days with carboplatin (CARBO), 500 mg/m(2), and doxorubicin (DOXO), 60 mg/m(2) for HR-HB patients.
Study: 9092746
Drug: Glycolic acid
Normalized name: Glycolic Acid
DrugBank: Glycolic acid (DB03085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycolic acid treatment
Study: 9092746
Drug: Jessner's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jessner's solution treatment
Study: 8250708
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg bolus followed by 37.5 mg/h)
Study: 8250708
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g every 6 hours suspended in 20 mL of sterile water)
Study: 26762204
Drug: Bevacizumab (beva)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (beva) + CCNU chemotherapy
Study: 22711898
Drug: Rizatriptan (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan (5 mg for < 40 kg, 10 mg for ≥ 40 kg)
Study: 18272093
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg morphine then 0.025 mg/kg every 5 minutes (group A)
Study: 18272093
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg morphine then 0.05 mg/kg every 5 minutes (group B)
Study: 12778779
Drug: Infusions taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusions taken directly from a warming box in the ambulance (Group A, n = 25)
Study: 12778779
Drug: Infusions taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusions taken from the warming box and packed in an insulation device (Group B, n = 25)
Study: 9704787
Drug: Fetal plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fetal plasma interleukin‐6 concentrations > 11 pg/mL
Study: 9704787
Drug: Fetal plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fetal plasma interleukin‐6 concentrations ≤ 11 pg/mL
Study: 29513248
Drug: Endoscopic sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic sclerotherapy with 3-day substitution therapy of deficient factors VIII or IX
Study: 26918279
Drug: TAS-102 (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-102 (35 mg/m²) administered in a single dose during pharmacokinetic phase and twice-daily doses in 28-day cycles during repeated administration phase.
Study: 26918279
Drug: TAS-102 (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-102 (twice-daily doses) during repeated administration phase.
Study: 26918279
Drug: TAS-102 (postprandial
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-102 (postprandial administration).
Study: 16463831
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (20 mmol over 10 min followed by an infusion of 4 mmol/h)
Study: 10398629
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg tablet) once daily at bedtime for up to 12 weeks
Study: 10398629
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily at bedtime for up to 12 weeks
Study: 7570431
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly physiotherapy (group A) after initial twice weekly sessions for 3 months
Study: 7570431
Drug: Once monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once monthly physiotherapy (group B) after initial twice weekly sessions for 3 months
Study: 2112131
Drug: 4% lidocaine
Normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% lidocaine inhalation
Study: 378094
Drug: Inderectic (propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inderectic (propranolol 80 mg and bendrofluazide 2.5 mg, given twice daily)
Study: 378094
Drug: Free combination
Normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free combination of propranolol and bendrofluazide (given as separate tablets)
Study: 6840831
Drug: liver-solution with
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: liver-solution with 45% branched chain amino acids
Study: 6840831
Drug: conventional solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional solution with 10.5% branched chain amino acids
Study: 30591575
Drug: Daily SMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SMS quizzes
Study: 30591575
Drug: Daily SMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SMS quizzes with daily readings and online CME courses
Study: 24506265
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml 1% methylene blue and 16 ml 0.5% marcaine
Study: 24506265
Drug: 16 ml
Normalized name: 16 ML Mvasi 25 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 ml 0.5% marcaine and 4 ml saline (placebo)
Study: 19679221
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Glucosamine, Ibuprofen, Placebo)
Study: 15843221
Drug: 7-oxo-dehydroepiandrosterone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-oxo-dehydroepiandrosterone (25 mg daily transdermally for 8 days)
Study: 9791752
Drug: Vaccinated children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinated children (PRP-T vaccine)
Study: 7881681
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy (STD)
Study: 7881681
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of standard therapy with exercise (EX)
Study: 2875594
Drug: Midazolam 10
Normalized name: midazolam 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 10 mg
Study: 31170712
Drug: Bardoxolone methyl
Normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bardoxolone methyl (Bard) 20 mg once daily
Study: 23934045
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg parecoxib injected intravenously 30 min before surgery and every 12 h for 2 days
Study: 23934045
Drug: Incision-local block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incision-local block with 5 ml of 0.5% ropivacaine and 20 ml of physiological saline every 12 h for 2 days
Study: 21114583
Drug: Combined metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined metformin and clomiphene citrate (CC)
Study: 20003788
Drug: Remifemin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifemin 20 mg bid po for 12 weeks
Study: 20003788
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg qd po for 12 weeks
Study: 15532067
Drug: Test bromazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test bromazepam formulation (6 mg)
Study: 15532067
Drug: Reference bromazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference bromazepam formulation (6 mg)